Office of Research & Development |
  |
Talk to the Veterans Crisis Line now
An official website of the United States government
Project Number: | I01BX004739-01A2 |
| Title: | Optimization and preclinical characterization of anthranilamide derivatives for Alzheimer prevention |
| Principal Investigator: | William (zhiming) Suo |
| Location: | Kansas City, MO |
| Congressional District Code: | 5 |
| Research Service: | Biomedical Laboratory R&D |
| Project Period: | October 2020 - September 2024 |
| FY 2021 Funding Amount: | $391,126 |
| Total Award Amount (all years): |
$1,776,630 |
| Abstract: |
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt: Alzheimer's disease (AD) is a devastating dementia without a disease-modifying therapy. According to FDA, AD clinical trials are over 200 but so far have made zero success in slowing AD progression. This continuous failure speaks for the difficulty of this task and calls for re-evaluating the existing therapeutic strategies. As a neurodegenerative disorder, neuronal death is fundamental to AD pathogenesis. Current therapeutic strategies concentrate on combating neurotoxic insults implicated in... |